Perinatal morphine exposure induces chromatin and transcriptomic remodeling to alter immune and metabolic function

Category	Detail
Condition	Neonatal Opioid Withdrawal Syndrome (NOWS)
Key Mechanisms	Altered chromatin structure and gene expression affecting immune and metabolic functions.
Target Population	Infants exposed to opioids in utero.
Care Setting	Research study using rodent models.

Perinatal opioid exposure leads to lasting changes in hypothalamic neurons.
Differential gene expression and histone modifications are linked to immune and metabolic pathways.
Cytokine levels are suppressed in morphine-exposed mice under both baseline and immune-challenged conditions.
Transcription factor 4 (TCF4) identified as a key regulatory hub.
Long-term physiological impacts of early-life opioid exposure include altered weight and body temperature.

Monitor for symptoms of NOWS including tremors, irritability, feeding difficulty, and respiratory dysfunction.

Consider multi-omic approaches to understand the effects of perinatal opioid exposure.

Increased risk of cognitive, behavioral, and physical deficits in children exposed to opioids in utero.

Pregnant women prescribed opioids.

Awareness of potential risks associated with opioid use during pregnancy is critical.

Utilize rodent models to investigate molecular mechanisms of NOWS.
Integrate RNA sequencing and chromatin immunoprecipitation sequencing for comprehensive analysis.
Focus on immune and metabolic pathways when assessing long-term effects of opioid exposure.

Clinical Scorecard: Perinatal Exposure to Morphine Alters Chromatin Structure and Gene Expression, Affecting Immune and Metabolic Functions